Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.47 |
| ▸ | KDM4A | O75164 | 1/20 | 0.47 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.47 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27056807 | 1.00 | KDM4C (0.47) | KDM4CKDM4APHF8KDM2ALTA4H | |
| SCHEMBL6726304 | 1.00 | KDM4C (0.47) | KDM4CKDM4APHF8KDM2ALTA4H | |
| SCHEMBL5571309 | 1.00 | KDM4C (0.47) | KDM4CKDM4APHF8KDM2ALTA4H | |
| SCHEMBL13684770 | 1.00 | KDM4C (0.47) | KDM4CKDM4APHF8KDM2ALTA4H | |
| SCHEMBL26203804 | 1.00 | KDM4C (0.47) | KDM4CKDM4APHF8KDM2ALTA4H | |
| SCHEMBL13684744 | 1.00 | KDM4C (0.47) | KDM4CKDM4APHF8KDM2ALTA4H | |
| SCHEMBL15197954 | 0.98 | LTA4H (0.45) | KDM4CKDM4APHF8KDM2ALTA4H | |
| SCHEMBL11117049 | 0.90 | CA1 (0.44) | KDM4CKDM4APHF8KDM2ALTA4H | |
| SCHEMBL26202270 | 0.88 | KDM4C (0.44) | KDM4CKDM4APHF8KDM2ALTA4H | |
| SCHEMBL9973392 | 0.87 | CES2 (0.48) | LTA4HLMNACES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025863-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230321251-A1 | LIPOSOME FORMULATION CONTAINING ANTIBACTERIAL AGENT | OSAKA UNIVERSITY (JP) | 2023-10-12 | — | — | US | disclosed |
| US-20230227826-A1 | UNA OLIGOMERS FOR THE TREATMENT OF POLYGLUTAMINE DISEASES | ARCTURUS THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230158159-A1 | CHIMERIC DEGRADERS OF CYCLIN-DEPENDENT KINASE 9 AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321251-A1 | LIPOSOME FORMULATION CONTAINING ANTIBACTERIAL AGENT | LIPA, LIPG, LIPC | KDM4C 3707/4885KDM4A 3081/4885PHF8 3678/4885 |
| US-20230227826-A1 | UNA OLIGOMERS FOR THE TREATMENT OF POLYGLUTAMINE DISEASES | HNRNPR, HNRNPK, ATXN2 | KDM4C 4179/4885KDM4A 4386/4885PHF8 2712/4885 |
| US-20230158159-A1 | CHIMERIC DEGRADERS OF CYCLIN-DEPENDENT KINASE 9 AND USES THEREOF | CDK9, CDK19, CRBN | KDM4C 507/4885KDM4A 388/4885PHF8 1832/4885 |
| US-20240025863-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | SOS1, SOS2, SOST | KDM4C 4432/4885KDM4A 3478/4885PHF8 3065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.